Ed Arce
Stock Analyst at WestPark Capital
(4.20)
# 425
Out of 5,064 analysts
431
Total ratings
45.43%
Success rate
16.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $12.73 | +119.95% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $34.69 | -13.52% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.69 | +1,627.86% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $5.40 | +1,288.89% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $6.26 | +858.47% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.55 | +383.87% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.30 | +202.33% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $5.35 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.34 | +347.76% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.21 | +660.04% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $38.50 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.35 | +5,417.24% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.55 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.67 | +379.76% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $219.35 | -84.04% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $54.31 | +38.10% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $70.94 | +1.50% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $547.96 | -26.09% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.42 | +1.48% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $33.59 | +182.82% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.31 | +16.01% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $38.27 | +25.42% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $26.32 | -71.50% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.39 | +1,194.67% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.68 | -17.09% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.61 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $28.46 | -12.16% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.84 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.19 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $34.26 | -79.57% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $45.14 | -53.48% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.97 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $12.73
Upside: +119.95%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $34.69
Upside: -13.52%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.69
Upside: +1,627.86%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $5.40
Upside: +1,288.89%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $6.26
Upside: +858.47%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.55
Upside: +383.87%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.30
Upside: +202.33%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.35
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.34
Upside: +347.76%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.21
Upside: +660.04%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $38.50
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.35
Upside: +5,417.24%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.67
Upside: +379.76%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $219.35
Upside: -84.04%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $54.31
Upside: +38.10%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $70.94
Upside: +1.50%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $547.96
Upside: -26.09%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.42
Upside: +1.48%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $33.59
Upside: +182.82%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.31
Upside: +16.01%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $38.27
Upside: +25.42%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $26.32
Upside: -71.50%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.39
Upside: +1,194.67%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.68
Upside: -17.09%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $28.46
Upside: -12.16%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.84
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.19
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $34.26
Upside: -79.57%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $45.14
Upside: -53.48%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.97
Upside: -